Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Amneal Pharmaceuticals, Inc.
AMRX·Healthcare
D ★Strong Sell
Current$19.45
Nov 6, 2026

Amneal's expanding biosimilar and specialty portfolio supports long-term earnings growth, but elevated valuation, acquisition-related leverage, and weak cash conversion create substantial downside risk.

Score
46
Pharvaris N.V.
PHVS·Healthcare
D ★Strong Sell
Current$36.27
Aug 25, 2026

Pharvaris possesses a promising oral bradykinin antagonist pipeline for HAE, but a premium valuation, pre-revenue cash burn, and intense competition from first-to-market oral peers create an unfavorable risk-reward profile requiring extreme commercial execution.

Score
46
Trevi Therapeutics, Inc.
TRVI·Healthcare
D ★Strong Sell
Current$14.82
Nov 12, 2026

Trevi Therapeutics could build a valuable chronic-cough franchise through Haduvio's late-stage clinical programs, but unproven commercialization, widening losses, clinical binary risk, and substantial dilution weaken its current investment appeal.

Score
45
Xenon Pharmaceuticals Inc.
XENE·Healthcare
D ★Strong Sell
Current$42.10
Nov 12, 2026

Xenon's promising epilepsy franchise and substantial cash reserves offer significant long-term potential, but unproven commercialization, psychiatric safety concerns, and material dilution undermine its near-term risk-reward profile.

Score
45
ImmunityBio, Inc.
IBRX·Healthcare
D ★Strong Sell
Current$6.67
Nov 12, 2026

ImmunityBio could build a substantial bladder cancer immunotherapy franchise through ANKTIVA label expansion and global commercialization, but persistent cash burn, dilution, and demanding valuation undermine shareholder risk-reward.

Score
45
Vaxcyte, Inc.
PCVX·Healthcare
D ★Strong Sell
Current$66.88
Nov 10, 2026

Vaxcyte's promising 31-valent pneumococcal vaccine franchise and successful pivotal clinical results create substantial commercial potential, but accelerating cash burn, financing dilution and unproven profitability threaten shareholder returns.

Score
45
Perimeter Solutions, Inc.
PRM·Materials
D ★Strong Sell
Current$29.50
Nov 8, 2026

Perimeter Solutions owns a highly profitable wildfire-retardant franchise with industrial acquisition opportunities, but weak cash conversion, rising leverage, founder-related obligations, and demanding valuation threaten shareholder returns.

Score
45
Immunovant, Inc.
IMVT·Healthcare
F Avoid
Current$37.04
Nov 12, 2026

Immunovant's IMVT-1402 could become a valuable multi-indication autoimmune therapy following promising clinical results, but the absence of commercial revenue, substantial dilution, and pivotal-trial uncertainty create significant downside risk.

Score
44
IonQ, Inc.
IONQ·Technology
F Avoid
Current$32.62
Nov 8, 2026

IonQ offers exceptional long-term quantum technology growth potential through proprietary hardware, major contracts, and integrated manufacturing, but persistent cash burn, substantial dilution, and demanding valuation threaten shareholder returns.

Score
44
Kymera Therapeutics, Inc.
KYMR·Healthcare
F Avoid
Current$126.29
Nov 2, 2026

Kymera's innovative oral protein degraders could unlock major immunology markets, but its pre-commercial status, substantial valuation, and shareholder dilution leave investors highly exposed to clinical setbacks.

Score
44
MiniMed Group, Inc.
MMED·Healthcare
F Avoid
Current$22.50
Sep 14, 2026

MiniMed has a credible diabetes-technology growth engine led by Flex, CGM attachment and a strong pipeline, but negative free cash flow, low current returns and an expensive forward multiple make the post-spin risk-reward unattractive today.

Score
44
Praxis Precision Medicines, Inc.
PRAX·Healthcare
F Avoid
Current$346.21
Nov 12, 2026

Praxis could establish a valuable precision-neuroscience franchise through two imminent FDA decisions and a broad clinical pipeline, but substantial dilution, persistent cash burn, and demanding expectations create significant downside risk.

Score
43